Table 6. Utirik adult body burdens, 1979 (D = ratio-derived; NA = not analyzed). Males Body burden (uci) Females Number of . persons Body burden (wi) - All adults Number of persons _ Body burden ( Wi) Number of persons Days post return 606, D D 4.0x1073 9.7x1074 550 3.5x1071* 2:7x1071 3.7x1072 D 3.1x1073 7.6x1074 2 14 3.5x1073 8.7x1074 1.6x1l071 3.3x1072 15 2.1x1071 3.5x1l072 2464 3924 29 1734 2464 55 ie D 1.7x1071 1.6x107! 1.6x107! 6114 90, 1.4x1073 5 2.4x1073 2 1.7x1073 NA 1.5x1074 12 14 NA 1.5xl074 12 17 NA 1.5x1074 24 31 8669 9225 4.1x1071 NA 2.7x1071 NA 3.3x1071 NA 1004 2.6x107! 9 1.3x107! 13 1.8x107! 22 7213 1.2x1073 13765 2.9x1071 1.2x1071 6.2x1072 5 15 27 19 1.3x1073 2.0x107! 6 7.8x1072 4.3x1072 15 21 17 1.3x1079 2.5x1071 1.0x107! 5.3x1072 7 11 30 48 36 1734 7213 1734 8309 9225 *Measured at Argonne, not used in dosimetry. tod C33 a7 C23 co CF 90sr, and 137¢s. The standard deviation on this ratio is 15%. These ratios were determined only when the body burden for the nuclide of interest had reached a maximum. Thus a significant time passed on Rongelap, 2 to 3 years post return, before a body burden comparison was valid. It was observed, in all cases, that the population mean body burdens were lower by a factor of 3 than the highest for any individual in the population. The population mean dose equivalent and maximum dose equivalent likewise differed by a factor of 3. The population average daily activity inges~ tion rate and maximum value differed by a factor of 4. For the nuclides 37¢s and 6>2n, a substantial sub-group in the population, children and infants, received a dose equivalent higher than the population mean value. - 118 -